Syngene Accelerates Therapeutic Discovery with Target Focused-Modality Agnostic Approach and Deep Expertise Across Specialty Platforms (PROTACs, Conjugates, T-Cell, Gene Therapy)

Syngene accelerates discovery

Check out our interview with Kenneth Barr, SVP, Discovery Services, Syngene as he talks about targeted protein degradation emerging as a transformative new therapeutic modality.

Sygnene is accelerating therapeutic discovery and we’re thrilled they are a part of our Science Exchange Contracted™ network of 3,300+ CROs, CMOs, and academic labs offering their services to help research organizations accelerate drug discoveries and innovation. […]

Read More…